0001567619-20-012894.txt : 20200702
0001567619-20-012894.hdr.sgml : 20200702
20200702200826
ACCESSION NUMBER: 0001567619-20-012894
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200702
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Marango Jotin
CENTRAL INDEX KEY: 0001777513
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32001
FILM NUMBER: 201011755
MAIL ADDRESS:
STREET 1: C/O APTOSE BIOSCIENCES INC.
STREET 2: 251 CONSUMERS ROAD, SUITE 1105
CITY: TORONTO
STATE: A6
ZIP: M2J 4R3
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aptose Biosciences Inc.
CENTRAL INDEX KEY: 0000882361
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 251 CONSUMERS ROAD
STREET 2: SUITE 1105
CITY: TORONTO
STATE: A6
ZIP: M2J 4R3
BUSINESS PHONE: 647-479-9828
MAIL ADDRESS:
STREET 1: 251 CONSUMERS ROAD
STREET 2: SUITE 1105
CITY: TORONTO
STATE: A6
ZIP: M2J 4R3
FORMER COMPANY:
FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.)
DATE OF NAME CHANGE: 20140905
FORMER COMPANY:
FORMER CONFORMED NAME: LORUS THERAPEUTICS INC
DATE OF NAME CHANGE: 19990308
FORMER COMPANY:
FORMER CONFORMED NAME: IMUTEC PHARMA INC
DATE OF NAME CHANGE: 19970113
4
1
doc1.xml
FORM 4
X0306
4
2020-07-02
0
0000882361
Aptose Biosciences Inc.
APTO
0001777513
Marango Jotin
C/O APTOSE BIOSCIENCES INC.
251 CONSUMERS ROAD, SUITE 1105
TORONTO
A6
M2J 4R3
ONTARIO, CANADA
0
1
0
0
Senior VP, Chief Bus. Officer
Common Shares
2020-07-02
4
S
0
20946
6.3398
D
179054
D
Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 40,000 restricted stock units, previously reported on a Form 4/A filed with Securities and Commission on May 7, 2020.
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
/s/ Janet Clennett as attorney-in-fact for Jotin Marango
2020-07-02